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Background Neural tube defects (NTDs) remain an important, preventable cause
of mortality and morbidity. High-income countries have reported
large reductions in NTDs associated with folic acid supplementation
or fortification. The burden of NTDs in low-income countries and the
effectiveness of folic acid fortification/supplementation are unclear.
Objective To review the evidence for, and estimate the effect of, folic acid
fortification/supplementation on neonatal mortality due to NTDs,
especially in low-income countries.
Methods We conducted systematic reviews, abstracted data meeting inclu-
sion criteria and evaluated evidence quality using adapted Grading
of Recommendations, Assessment, Development and Evaluation
(GRADE) methodology. Where appropriate, meta-analyses were
performed.
Results Meta-analysis of three randomized controlled trials (RCTs) of folic
acid supplementation for women with a previous pregnancy with
NTD indicates a 70% [95% confidence interval (CI): 35–86] reduction
in recurrence (secondary prevention). For NTD primary prevention
through folic acid supplementation, combining one RCT with
three cohort studies which adjusted for confounding, suggested a
reduction of 62% (95% CI: 49–71). A meta-analysis of eight
population-based observational studies examining folic acid food for-
tification gave an estimated reduction in NTD incidence of 46% (95%
CI: 37–54). In low-income countries an estimated 29% of neonatal
deaths related to visible congenital abnormalities are attributed to
NTD. Assuming that fortification reduces the incidence of NTDs, but
does not alter severity or case-fatality rates, we estimate that folic
acid fortification could prevent 13% of neonatal deaths currently
attributed to congenital abnormalities in low-income countries.
Discussion Scale-up of periconceptional supplementation programmes is chal-
lenging. Our final effect estimate was therefore based on folic acid
fortification data. If folic acid food fortification achieved 100% pop-
ulation coverage the number of NTDs in low-income countries
could be approximately halved.
Conclusion The evidence supports both folic acid supplementation and fortifi-
cation as effective in reducing neonatal mortality from NTDs.
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Background
Neural tube defects (NTDs) are congenital malforma-
tions of the brain and spinal cord caused by failure of
the neural tube to close between 21 and 28 days fol-
lowing conception. Defects range from anencephaly,
through encephalocoeles to spina bifida, which is
more variable in severity and effect (Table 1).
Anencephaly is invariably associated with death as a
stillbirth, a neonatal death or occasionally a post-neo-
natal death. Encephalocoele and spina bifida may be
associated with neonatal death, infant death or with
impairment which is frequently severe in the absence
of surgery—e.g. lower limb paralysis, incontinence,
convulsions and frequent central nervous system
(CNS) infections. Even with surgery to close the
spinal defect and insert ventriculo-peritoneal shunts,
spina bifida is associated with premature mortality
and a high degree of disability.1 Less severe defects
include spina bifida occulta. Whilst these can have
long-term neurological sequelae, they rarely cause
neonatal death. This article therefore focusses on
livebirths with open NTDs. It should, however, be
noted that in countries with antenatal ultrasound
(USS) available, the true effect of folic acid on pre-
venting affected foetuses will be underestimated.
NTDs are an important cause of mortality and morbid-
ity globally with a conservative estimated incidence of
4300 000 new cases a year2 resulting in an estimated
41 000 deaths and 2.3 million disability-adjusted life
years (DALYS).3 They thus comprise about one-tenth
of the burden of all congenital conditions and constitute
the third largest congenital burden after congenital
heart disease and Down’s syndrome.3
Over 95% of all NTDs are first occurrence, with a
small proportion being repeat events in women with
a previously affected pregnancy.6 Risk factors include
genetic factors (which may explain the high preva-
lence in certain populations, e.g. in Ireland and
some provinces in China), environmental factors, par-
ticularly folic acid deficiency at the time of concep-
tion, diabetes and obesity. In most studies from
countries where a folate-rich diet is not available to
Table 1 Categories of neural tube defects, their features and sequelae4–5
Anencephaly Encephalocoele Spina bifida cystica
Cause Failure of closure of the
anterior (cranial)
neural arch
Failure of closure of the
anterior (cranial) neural
arch at a later stage of
embryogenesis than
anencephaly
Failure of closure of the
posterior (caudal) vertebral
arch. Most commonly
affecting the lumbo-sacral
region and usually associated
with hydroecephalus
(blockage of drainage of
the cerebrospinal fluid)
Clinical features Absence of variable
amounts of brain,
spinal cord, nerve
roots and meninges
Sack containing brain tissue
herniates through midline
skull defect, usually occipital
Herniation of the meninges
through a defect in the
lower spine (meningocoele)
or severe forms include also
herniation of dysplastic spinal
cord (myelomeningocoele)
Hydrocephalus resulting in
extra fluid around the brain
and raised intracranial pressure.
Prognosis and
sequelae
Stillbirth or
neonatal death
Variable–high mortality from
meningitis.
With surgical repair long-term
outcome varies from normal
function to severe
multi-domain impairment
Variable levels of disability
including:
Neurological: sensory and
motor defects, learning
disabilities, epilepsy.
Orthopaedic: contractures,
joint dislocation,
talipes.
Functional: bladder and
bowel dysfunction.
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all, NTDs exhibit a social gradient with the most eco-
nomically disadvantaged in a population having the
highest incidence.7–10 Even in high-income countries,
lower maternal education status is associated with
higher risk of NTDs.8,11
Over the past decades many countries have
reported a reduction in prevalence at birth of
NTDs.12 In one series an overall 93% decrease in prev-
alence at birth was accounted for by a combination
of second-trimester screening and termination of
affected pregnancies (34%) and an underlying
decrease in the prevalence of affected conceptions
(59%), in part explained by folic acid supplementa-
tion.13 The role of periconceptional folic acid in
the prevention of NTDs has been investigated since
the 1980s. High-quality evidence, particularly from
randomized controlled trials (RCTs) in Hungary
which showed a reduction in recurrent NTDs with
folic acid supplementation,14 led to many high-
income countries adopting policies recommending
supplementation for women planning pregnancy.15
Commonly, this involved recommending a 0.4 mg
folic acid tablet daily to all women planning preg-
nancy and 4 mg folic acid to those with a previous
pregnancy affected by NTDs.
A successful periconceptional folic acid supplemen-
tation programme requires a high proportion of preg-
nancies to be planned as well as easy access to a
functioning health system and effective local social
marketing interventions.16 However, unplanned preg-
nancies may account for one-third to one-half of all
pregnancies even in high-income settings17,18 and
thus supplementation policies have had limited
impact at a population level, even in high-income
countries.19 The public health impact of folic acid sup-
plementation is likely to be lower in low-income
countries where unplanned pregnancies are more
common and access to, and cost of, folic acid are
greater barriers.
Another option for ensuring increased folic acid
intake around the time of conception is folic acid for-
tification of food. Interest in this approach
has increased recently and it has been implemented
in 57 countries to date.20 In many cases the fortifica-
tion policy is driven by the food industry.
However, the effectiveness of fortification is depen-
dent on dietary norms—e.g. flour fortification may
be ineffective in some South Asian and African coun-
tries if many families, especially the poor who are
most at risk, do not regularly eat purchased flour
products.
A recent US Preventive Services review has exam-
ined the growing evidence that folic acid supplemen-
tation in high-income countries provides benefit in
reduction of risk for first NTDs.21 Our study provides
a quantitative estimate of the effect folic acid on the
reduction in risk using evidence for folic acid fortifi-
cation and supplementation.
Objective
The objective of this article is to estimate the effect
of folic acid on neonatal mortality from NTDs
in low-income countries, and hence to estimate
the proportionate mortality reduction for visible con-
genital abnormalities. This estimate of effect will
facilitate country-specific analysis using the LiST
tool to estimate reductions in numbers of neonatal
deaths.
Methods
We systematically reviewed the published literature to
identify studies of periconceptional folic acid use
(supplementation or fortification) for the preven-
tion of neonatal NTDs mortality and morbidity on
24 February 2009 and an updated search was per-
formed on 13 September 2009. We searched
PubMed, EMBASE, Cochrane Libraries and all World
Health Organization Regional Databases and included
publications in any language.22 Snowball searching
was used whereby literature referenced in key
papers was included. Combinations of the following
search terms were used: ‘neural tube defect’, ‘neo-
natal mortality/morbidity’, ‘folic acid’, ‘pregnancy’,
‘newborn, infant’ (Figure 1).
Inclusion/exclusion criteria
We applied the Patient, Intervention, Comparison,
and Outcome (PICO) format to define the studies to
be included as follows. The ‘population’ of interest
were neonates and the ‘interventions’ being reviewed
were the effect of folic acid supplementation (using
folic acid tablets 0.36 mg once daily to 5 mg once a
week) or of food fortification with folic acid. The
comparison group were those neonates born after
pregnancies without folic acid fortification or supple-
mentation. The outcomes of interest were NTDs and
mortality associated with NTDs (Table 1). In this
study, we considered both randomized trials
and observational studies meeting these criteria
(Figure 1). We excluded studies not fulfilling the
inclusion criteria and any duplicate reports of trials
or studies. Possible adverse effects of folic acid sup-
plementation and fortification were not addressed as
part of this review.
Abstraction, analyses and summary measures
All studies meeting the inclusion criteria were
abstracted onto a standardized abstraction form
for each outcome of interest.22 Each study was
assessed and graded according to the Child Health
Epidemiology Reference Group (CHERG) adaptation
of the Grading of Recommendations, Assessment,
Development and Evaluation (GRADE) technique.23
The evidence was summarized by outcome including
a qualitative assessment of study quality and sources
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of bias as adapted from the Cochrane review hand-
book. Evidence from low/middle-income countries
was assessed separately based on the World Bank
classification of income groups. CHERG Rules for
Evidence Review were applied to the collective evi-
dence to provide an estimate for reduction in neonatal
NTD mortality.
Separate meta-analyses were planned for folic acid
supplementation effect on secondary and primary pre-
vention, as well as a third meta-analysis of the effect
of folic acid fortification. Meta-analyses were con-
ducted with STATA version 10 statistical software.24
Heterogeneity was assessed using chi-square test.
When evidence of heterogeneity was present
(P< 0.10), a random effects model was used, other-
wise a fixed effect was assumed. Appropriate sum-
mary risk ratios and corresponding 95% confidence
interval (CI) are reported.
Results
The search strategy from all listed databases identified
1667 records (Figure 1). After initial screening of the
title or abstract we reviewed 30 papers for the
outcome measures of interest. Nineteen papers were
included in the final database (Supplementary Table 1
available at IJE online). One relevant Cochrane
Review of periconceptional folic acid supplementation
was available.25 This review combined, in one
meta-analysis, three trials to prevent recurrence of
NTDs with one RCT of folic acid supplementation
for prevention of first occurrence of NTDs.
(i) Prevention of the recurrence of neural tube defects: We
identified three RCTs of the effect of folic acid
supplementation on the risk of recurrence of
NTDs in women with previously affected preg-
nancies.26–28 A meta-analysis of these three trials
resulted in a risk ratio (RR) of 0.30 (95% CI:
0.14–0.65; Figure 2a) However, of greater inter-
est from a public health perspective, is preven-
tion of first occurrence.
(ii) Prevention of first occurrence of neural tube defects
through supplementation: Eight studies of the
effect of folic acid supplementation on incidence
of first occurrence of NTDs were identified. No
randomized trials of folic acid supplementation
reported the effect on neonatal mortality.
Total search results
:1667 unique
Cochrane = 1
Pubmed= 1640
EMBASE = 603
WHO regional databases = 106
Studies remaining after 
screening title or abstract
(n= 30)
n=11 excluded after review of
the paper
19
studies
Observational (n=15)RCT (n= 4)
DATABASES
PubMed, Cochrane, 
EMBASE, WHO regional 
databases
SEARCH TERMS
‘‘Neural Tube Defects”“Folic Acid”
“newborn infant”“pregnancy”
Mortality and Morbidity
2 folic fortification
Mortality
0
Excluded
Morbidity only =13
5 folic suppl
8 fortification
2 suppland fort
Morbidity
4 (3 prevention of recurrence)
Figure 1 Synthesis of study identification in the review of the effect of folic acid on neonatal mortality form neural tube
disorders. Detailed Pubmed search terms: ("folic acid"[MeSH Terms] OR ("folic"[All Fields] AND "acid"[All Fields]) OR "folic
acid"[All Fields]) AND ("neural tube defects"[MeSH Terms] OR ("neural"[All Fields] AND "tube"[All Fields] AND
"defects"[All Fields]) OR "neural tube defects"[All Fields] OR ("neural"[All Fields] AND "tube"[All Fields] AND "defect"[All
Fields]) OR "neural tube defect"[All Fields]) AND ("infant, newborn"[MeSH Terms] OR ("infant"[All Fields] AND
"newborn"[All Fields]) OR "newborn infant"[All Fields] OR "neonate"[All Fields]) OR ("infant mortality"[MeSH Terms] OR
("infant"[All Fields] AND "mortality"[All Fields]) OR "infant mortality"[All Fields] OR ("neonatal"[All Fields] AND
"mortality"[All Fields]) OR "neonatal mortality"[All Fields]) OR ("women"[MeSH Terms] OR "women"[All Fields] OR
"female"[MeSH Terms] OR "female"[All Fields] OR "pregnancy"[MeSH Terms] OR "pregnancy"[All Fields] OR
periconceptual[All Fields] OR "peri conceptual"[All Fields]) Embase/ WHO regional databases: ‘neural tube defects’
‘folic acid’
FOLIC ACID TO REDUCE NEONATAL MORTALITY FROM NEURAL TUBE DISORDERS i113
Four before-and-after studies of education cam-
paigns, which all achieved coverage of folic acid
supplementation of <50%, were excluded.29–32
There was not strong evidence of heterogeneity
between the remaining four studies (one RCT14
and three cohort studies which adjusted for
confounding;33–35 P¼ 0.24; I2¼ 27.9%). A
meta-analysis of these four studies produced
an estimated risk ratio for the effect of folic
acid supplementation on the incidence of NTDs
of 0.38 (95% CI: 0.29–0.51; Figure 2b). Further
evidence that folic acid supplementation protects
against NTDs is provided by four case–control
studies which reported reductions in the inci-
dence of NTDs with folic acid supplementation
(0.4–0.8 mg) ranging from 35 to 75%.36–39
Including the four studies with poor coverage
in the meta-analysis resulted in an estimate of
0.63 (95% CI: 0.48–0.82). This lower estimate of
effect is likely to reflect the difficulty of achiev-
ing high coverage of a supplementation pro-
gramme. (see Supplementary Figure 1 available
at IJE online).
(iii) Primary prevention of neural tube defects through
fortification: Ten before-and-after studies asses-
sing the effect of mandatory folic acid fortifica-
tion on the incidence of NTDs were also
abstracted. One study was excluded40 as
it was performed in a setting with routine ante-
natal ultrasound screening for congenital
abnormalities, high numbers of terminations of
affected pregnancies and reported only birth
certificate data. Eight of the remaining studies
from Chile,41 South Africa,42 Argentina,43
USA44 and Canada31,32,45,46 showed evidence
of heterogeneity (P¼ 0.002; I2¼ 69.2%). A
random-effects meta-analysis of all eight stu-
dies produced an estimated risk ratio of 0.54
(95% CI: 0.46–0.63; Figure 3). The heterogene-
ity observed appears to be largely attributable to
one of the Canadian studies.31 If this study is
excluded from the analysis there is no longer
strong evidence of heterogeneity (P¼ 0.26;
I2¼ 22.8%). The risk ratio is little changed
(0.58). The outlying study was relatively small,
with a high baseline rate of NTDs (4.4/1000)
compared with the other studies, but was oth-
erwise unexceptional. Restricting the analysis
to the three studies from middle-income
countries28,41–43 produced little change in the
estimated risk ratio (0.56; (95% CI: 0.50–0.63).
These results are consistent with the final study
retrieved of vital registration data from Oman
reporting a 62% reduction in NTDs incidence
(from 1.6 to 0.6 per 1000 live births) after
folic fortification; this study was excluded
from the meta-analysis as no detailed point
estimate or numbers of cases were reported.47
Sensitivity analyses indicate little difference in
the estimates using the different inclusion cri-
teria and meta-analysis methods (Figure 4).
Overall
(I-squared = 0.0%, p = 0.867)
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1
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2
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RR (95% CI)
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%
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(a)
(b)
Figure 2 Meta analysis of the effect of folic acid supple-
mentation. (a) Prevention of recurrent neural tube disorders
(secondary prevention), Relative Risk (95% Confidence
Interval); Heterogeneity 2¼ 0.28 (degrees of freedom
(df¼ 2) P¼ 0.867, I2 (variation in RR attributable to heter-
ogeneity)¼ 0%, Test of RR¼ 1: z¼ 3.06, P¼ 0.002. (b)
Primary prevention of neural tube disorders, Relative Risk
(95% Confidence Interval), Heterogeneity 2¼ 4.16 (df¼ 3)
P¼ 0.244, I2 (variation in RR attributable to heterogene-
ity)¼ 27.9%, Test of RR¼ 1: z¼ 6.59, P< 0.001
NOTE: Weights are from random effects analysis
Overall
(I-squared = 69.2%, p = 0.002)
Williams 2002
Study
ID
De Wals
Liu 2004
Persad 2002
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Sayed 2008
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Figure 3 Meta-analysis (random effects) of the effect of
folic acid fortification on primary prevention of neural tube
defects. Heterogeneity 2¼ 22.73 (df¼ 7), P¼ 0.002, I2
(variation in RR attributable to heterogeneity)¼ 69.2%;
Estimate of between-study variance t2¼ 0.0295, Test of
RR¼ 1: z¼ 8.01, P< 0.001
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Quality of the evidence
The CHERG Rules for Evidence Review were applied22
(Table 2). The observed reduction in NTDs with folic
acid fortification or supplementation was large and
fairly consistent across the different study designs
and, indeed, between supplementation and fortifica-
tion. There is high-quality evidence for the effect
of periconceptional folic acid on occurrence of recur-
rent NTDs with an estimated reduction of 70%
(95% CI: 35–86) but this is not the question of pri-
mary interest for public health implementation.
In terms of direct cause-specific mortality evidence,
there is low-quality evidence for a cause-specific mor-
tality reduction from one large before-and-after study
of folic acid fortification of 360 994 births in
Argentina.43 This study reports a 57% reduction in
neonatal mortality from NTDs after the introduction
of folic acid fortification. In addition, one study
from South Africa (808 661 births) reported a 66%
reduction in perinatal mortality with folic acid forti-
fication.42 None of the higher quality trials addressed
the impact of folic acid on reducing mortality from
NTDs.
Our new meta-analysis for primary prevention of
NTD using folic acid supplementation suggests an
estimated reduction in primary occurrence of 62%
(95% CI: 49–71). We grade this evidence as moderate
quality, based on one RCT and three cohort studies
that are consistent, together with the high quality
evidence for a reduction in recurrence of NTDs.
Evidence for a protective effect of folic acid food
fortification comes from eight large before-and-after
population-based studies including 3047 cases of
NTDs. The estimated risk reduction associated with
food fortification is 46% (95% CI: 37–54). While the
studies are of low quality, the evidence grade allo-
cated is moderate since there are eight studies
which are very consistent and there is strong biolog-
ical plausibility based on the supplementation trials.
Assuming that folic acid has no effect on the ratio of
anencephaly to other spinal defects, and that the
case-fatality rates remain constant, the reduction in
mortality from NTDs would be equal to the reduction
in occurrence, i.e. 46%.
Estimation of the effect of folic acid food
fortification on neonatal deaths due to
congenital causes in low-income settings
The LiST tool is a tool which enables health planners
in low-income countries to investigate the likely effect
on maternal, neonatal and child mortality of different
policy options. Within the tool the number of neona-
tal deaths attributed to congenital causes is estimated
using a statistical model using mainly verbal autopsy
data as inputs. A major weakness of this approach is
that only deaths in newborns with visible congenital
malformations will be attributed to congenital causes.
For example, deaths due to congenital heart disease
will be misclassified. NTDs represent a high propor-
tion of deaths due to visible congenital malforma-
tions. Current global estimates for the number of
neonatal deaths due to congenital causes by region
are based on methods described previously48
(Table 3). Work in progress for the Global Burden
of Disease provides estimates of the number of neo-
natal deaths due to NTDs by region (Table 3). The
median percent of congenital abnormalities attributed
to NTDs is 29%. A 46% reduction in NTD deaths
would, therefore, be expected to reduce the number
of deaths due to visible congenital malformations by
29% 46%, i.e. 13%.
Discussion
NTDs remain an important yet potentially preventable
cause of neonatal mortality. Dietary change and selec-
tive termination of affected pregnancies has resulted
in severe NTDs rarely being seen in high-income
countries. Data from three randomized trials indicate
that periconceptional folic acid supplementation
has a large effect on the recurrence of NTDs
(70% reduction; 95% CI: 35–86). Four prevention-of-
first-occurrence studies indicate a reduction in inci-
dence of 62% (95% CI: 49–71). These two
meta-analyses are the first to separate the effects of
folic acid supplementation on NTD incidence from the
effect on NTD recurrence.
In addition, there is increasing, although lower qual-
ity evidence regarding folic acid fortification of food.
Our systematic review identified 10 before-and-after
Figure 4 Sensitivity analyses of the estimate of the effect
folic acid fortification using different inclusion criteria and
meta-analysis methods
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population-based studies of the effect of folic acid
food fortification on the occurrence of NTDs. These
large-scale studies consistently report substantial
reductions in the incidence of NTDs or in perinatal
or neonatal mortality due to NTDs. A meta-analysis
of the eight included studies suggests that food forti-
fication can reduce the incidence of NTDs by 46%
(37–54%). This is the first meta-analysis that we are
aware of for folic acid fortification and NTDs and
shows a substantial and consistent effect even in
large-scale programmes. Assuming that folic acid
affects NTD occurrence but not severity or case-fatality
rate, we assume that folic fortification will reduce
NTD-specific neonatal mortality by 46%. There is emer-
ging evidence that folic acid fortification reduces both
the incidence and the severity of NTDs,49–50 which
would make this assumption conservative.
The effect of folic acid on incidence and mortality
may be different in countries with higher baseline
rate of NTDs, poorer diets (with higher levels of
folate deficiency in women of child-bearing age) and
without screening for, or termination of, affected
pregnancies.
There is evidence of a complex dose–response
relationship with different fortification regimes,
depending on the initial average birth prevalence of
NTDs and the additional intake of folic acid.51
The estimate in this meta-analysis of folic acid-forti-
fication effect is based primarily on white popula-
tions. A study from the USA reported lower
background NTDs rates amongst black Americans
compared to Hispanic or white groups, but also a
reduced effect of folic acid fortification in the black
American group.52 In Australia, the 30% reduction in
the incidence of NTDs seen following the introduction
of the folic acid-supplementation recommendation
and voluntary food fortification was limited to the
white population, with no changes in the NTD rates
amongst the aboriginal populations seen across this
time period.53 However, one large study in China
Table 3 Estimated proportion of congenital abnormality deaths and numbers of neonatal deaths due to NTDs for 2005 by
region (low-income/high neonatal mortality countries)
Region
Estimated total number of
neonatal deaths due
to congenital abnormalities/yeara
(uncertainty range)
Estimated number
of neonatal deaths
due to NTDs/yearb
% of all neonatal
deaths from congenital
abnormalities that are
attributed to NTDs
Asia
Southeast 17 000 (10–40 000) 5000 29
Central 5000 (3–10 000) 1500 30
East 34 500 (9–135 000) 20 500 59
South 100 000 (26–270 000) 70 000 70
Asia total 156 500 (68–360 000) 97 000 62
N. Africa/ Middle East
North Africa 9500 (4–21 000) 3000 32
Middle East 20 000 (12–37 000) 5500 28
N. Africa/ Middle East Total 29 500 (18–49 000) 8500 29
Sub-Saharan Africa
West 34 500 (18 69 000) 8000 23
South 3000 (2–6000) 1000 33
East 30 000 (18–49 000) 6500 22
Central 12 000 (3–27 000) 2000 17
Sub-Saharan Africa Total 79 500 (55–122 000) 17 500 22
Other regions 41 000 (38–45 000) 8000 20
Total 306 500 (216–516 000) 131 000 43
aProvisional estimates for Child Health Epidemiology Reference Group for 193 countries using methods described previously.48 Note
that in high-mortality countries the input data is largely from Verbal Autopsy which under estimates congenital abnormalities,
especially those without obvious external manifestations.
bProvisional estimates by the Child Health Epidemiology Reference Group for 193 countries based on systematic searches for
prevalence data, and case-fatality rate data.
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found very high rates of NTDs, which were substan-
tially reduced by periconceptional folic acid.34
Prevalence studies in South Asia report very high
rates.54–56
We based our estimate on fortification rather than
supplementation. Although efficacy studies of supple-
mentation have shown a large potential biological
impact, the widespread adoption of policies of folic
supplementation in many high- and middle-income
countries have generally produced disappointing
results at a public health level. The barriers to supple-
mentation are likely to be even greater in low-income
countries and those with high levels of poverty
and poor health-care infrastructure. However, maxi-
mizing effectiveness of fortification in low-income
countries may also present challenges. What level of
folic fortification should be adopted? What vehicle
should be used? This is likely to be country/region
specific, dependent on the proportion of the popula-
tion who buy particular food staples, such as flour,
maize or rice. Despite intense efforts, folic acid forti-
fication may not reach the poorest, as was seen in
Guatemala.57
The main limitation of this review and the resulting
effect estimate is the lack of high-quality studies
reporting the impact of folic acid supplementation or
fortification on neonatal mortality. Our estimate for
folic fortification is based on low-quality before-and-
after population studies from Canada, the USA and
three middle-income countries to determine the
impact on incidence. Given the consistency of the
effect size across studies, the quality can be upgraded
to moderate, but once assumptions are applied to
‘translate’ this to mortality effect, the quality of the
estimate is again downgraded to low. Further, possible
sources of bias are that the review retrieved only pub-
lished articles and that a single person was responsible
for the screening and abstraction of the articles.
The proportion of neonatal deaths due to congenital
abnormalities is problematic. Congenital abnormal-
ities are under-reported in Verbal Autopsy and,
indeed, also in hospital-based data since only obvious
external abnormalities such as NTDs are detected yet
the most common lethal congenital abnormalities are
congenital heart disease, which are most likely to be
misclassified as pneumonia. Hence the proportion of
neonatal deaths attributed to congenital abnormalities
is underestimated and reflects only those deaths due
to clearly visible abnormalities. In addition, there may
be systematic, selective misclassification of live-born
babies with congenital abnormalities who die shortly
after birth as stillbirths ‘to protect the mother’. These
global estimates (Table 3) are particularly uncertain
for South Asia where both the prevalence of NTDs
appears to be especially high, based on four studies,
and yet the proportion of neonatal death attributed to
congenital conditions is based on verbal autopsy and
is low and very uncertain.48
The effects of folic acid on pregnancy outcome may
extend beyond NTDs. Recent studies have suggested a
possible effect on reducing spontaneous preterm
delivery58 and severe congenital heart disease.59 Any
benefit of universal folic acid food fortification on
pregnancy outcome needs to be balanced against
potential, but as yet unclear, adverse effects. There
is very limited evidence that the amount of
folic acid consumed from fortified foods has any
adverse effects. Even in the USA amongst those
who consume daily supplements with folic acid of
400 mg, the likelihood is low of exceeding a total
intake of 1000 mg/day.60–61 Very high serum folate
levels, higher than those usually associated with
fortification have been associated with potential
adverse effects, but strong evidence of causation is
lacking, e.g. masking of vitamin B12 deficiency
amongst individuals with pernicious anaemia in the
population and promoting progression of already
existing pre-neoplasms.62–65
Conclusion
This review provides further evidence of the effective-
ness of folic acid in reduction the incidence of NTDs. We
estimate conservatively that folic acid fortification
has the potential to prevent 46% of NTD incidence
and mortality, translating to 13% of neonatal deaths
due to visible congenital malformations. This estimate
is slightly lower than the 57% reduction in NTD neona-
tal mortality reported following food fortification
reported by one low-quality study in Argentina but
lies within the 95% CI for that study (95% CI: 33–73).
A larger effect may be seen with folic acid supple-
mentation, but the efficacy observed in supplementa-
tion trials has not been reproduced on a population
level apart from in China, and this may not be trans-
ferable given the unique system of premarital health
checks and a high percentage of planned pregnancies
at the time of the study. The scaling up of food for-
tification in high- and middle-income countries has
the potential to reach the majority of the population,
although the practicalities of scaling up of food
fortification in low-income countries with a high pro-
portion of subsistence farmers have yet to be docu-
mented, and careful evaluation of the effects on NTD
mortality and morbidity is also lacking. However, suc-
cessful scaling up of folic acid fortification would lead
to major reductions in the global burden of NTDs and
morbidity reductions are likely to be of even greater
public health significance than the mortality effects
which are the focus of this review.
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KEY MESSAGES
 Cause-specific mortality to act on: The proportion of congenital abnormality neonatal deaths that is
due to neural tube defects (NTDs).
 Cause-specific effect and range: Food fortification with folic acid is estimated to lead to a 46%
reduction in the incidence of and mortality from NTDs. Assuming NTDs to constitute cause for
29% of neonatal deaths due to visible congenital causes in low-income countries, folic acid food
fortification may lead to a 13% reduction of visible neonatal congenital deaths.
 Quality of input evidence: Moderate quality (eight before-and-after population-based studies on inci-
dence of NTDs, data consistent)
 Proximity of the data to cause-specific mortality effect: Low (effect on incidence) necessitating trans-
lation of the NTD-specific reduction to a reduction in neonatal deaths due to congenital
abnormalities.
 Limitations of the evidence: The evidence may underestimate the effect on low-income populations
based on comparison with one low-quality study reporting 57% reduction in neonatal mortality from
NTDs. Most are incidence studies from middle/high-income countries, the outcome is distal to mor-
tality and uncertain assumptions are applied to translate this to an estimated mortality effect. The
data on mortality due to congenital abnormalities in low-income settings is limited and likely to
reflect only obvious visible abnormalities.
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